EP4337204A4 - COMPOSITIONS CONTAINING BISFLUORALKYL-1,4-BENZODIAZEPINONE COMPOUNDS FOR THE TREATMENT OF CANCER - Google Patents
COMPOSITIONS CONTAINING BISFLUORALKYL-1,4-BENZODIAZEPINONE COMPOUNDS FOR THE TREATMENT OF CANCERInfo
- Publication number
- EP4337204A4 EP4337204A4 EP22808332.5A EP22808332A EP4337204A4 EP 4337204 A4 EP4337204 A4 EP 4337204A4 EP 22808332 A EP22808332 A EP 22808332A EP 4337204 A4 EP4337204 A4 EP 4337204A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- bisfluoralkyl
- cancer
- treatment
- compositions containing
- benzodiazepinone compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163187991P | 2021-05-13 | 2021-05-13 | |
| US202163214355P | 2021-06-24 | 2021-06-24 | |
| PCT/US2022/028956 WO2022241095A1 (en) | 2021-05-13 | 2022-05-12 | Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP4337204A1 EP4337204A1 (en) | 2024-03-20 |
| EP4337204A4 true EP4337204A4 (en) | 2025-04-16 |
Family
ID=89898822
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP22808332.5A Pending EP4337204A4 (en) | 2021-05-13 | 2022-05-12 | COMPOSITIONS CONTAINING BISFLUORALKYL-1,4-BENZODIAZEPINONE COMPOUNDS FOR THE TREATMENT OF CANCER |
Country Status (2)
| Country | Link |
|---|---|
| US (1) | US20240299411A1 (en) |
| EP (1) | EP4337204A4 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019215585A1 (en) * | 2018-05-06 | 2019-11-14 | Ayala Pharmaceuticals Inc. | Compositions comprising cd20 inhibitors and bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9763956B2 (en) * | 2012-06-19 | 2017-09-19 | The Broad Institute, Inc. | Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy |
| US20200179511A1 (en) * | 2017-04-28 | 2020-06-11 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| US20210040050A1 (en) * | 2018-05-06 | 2021-02-11 | Ayala Pharmaceuticals Inc. | Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof |
-
2022
- 2022-05-12 EP EP22808332.5A patent/EP4337204A4/en active Pending
- 2022-05-12 US US18/560,388 patent/US20240299411A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9763956B2 (en) * | 2012-06-19 | 2017-09-19 | The Broad Institute, Inc. | Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy |
| US20200179511A1 (en) * | 2017-04-28 | 2020-06-11 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| US20210040050A1 (en) * | 2018-05-06 | 2021-02-11 | Ayala Pharmaceuticals Inc. | Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof |
Non-Patent Citations (2)
| Title |
|---|
| See also references of WO2022241095A1 * |
| WANG JING ET AL: "APG-1252-12A induces mitochondria-dependent apoptosis through inhibiting the antiapoptotic proteins Bcl-2/Bcl-xl in HL-60 cells", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 51, no. 2, 6 June 2017 (2017-06-06), GR, pages 563 - 572, XP093008035, ISSN: 1019-6439, DOI: 10.3892/ijo.2017.4028 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4337204A1 (en) | 2024-03-20 |
| US20240299411A1 (en) | 2024-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3983433A4 (en) | NOVEL INTERLEUKIN-2 VARIANTS FOR CANCER TREATMENT | |
| EP4337329A4 (en) | COMBINATIONS FOR THE TREATMENT OF CANCER | |
| EA201990495A1 (en) | BIARY COMPOUNDS APPLICABLE AS IMMUNOMODULATORS | |
| EP4017489C0 (en) | DGD1202 FOR THE TREATMENT OF KRAS-MUTATED CANCERS | |
| EP4352042A4 (en) | Compounds for the treatment of SARS | |
| EA201990221A1 (en) | 1,3-DIHYDROXIPHENYL DERIVATIVES APPLICABLE AS IMMUNOMODULATORS | |
| EP3823653A4 (en) | PROGRAMMABLE BACTERIA FOR THE TREATMENT OF CANCER | |
| EP3589289A4 (en) | INHIBITION OF SMARCA2 FOR TREATMENT OF CANCER | |
| EP4085144A4 (en) | COMPOSITIONS FOR THE TREATMENT OF FRIEDREICH AAXIA | |
| EP3793544C0 (en) | BIFUNCTIONAL COMPOSITIONS FOR TREATING CANCER | |
| EP3490543A4 (en) | ASCORBIC ACID, CHINONE COMPOUND AND SODIUM GLUCOSE-COTRANSPORTER INHIBITOR FOR TREATING CANCER | |
| EP3576792A4 (en) | PROCEDURES, COMPOSITIONS AND KITS FOR TREATMENT OF CANCER | |
| EP3947460A4 (en) | MULTISPECIFIC AGENTS FOR TREATMENT OF CANCER | |
| EP4096675C0 (en) | Compositions for the treatment of long COVID | |
| EP4259639A4 (en) | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | |
| EP4003351A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | |
| EP4151227A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER | |
| EP4259638A4 (en) | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | |
| EP4178574A4 (en) | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING FIBROTIC DISEASES AND CANCER | |
| EP3471774A4 (en) | PORPHYRINE COMPOUNDS AND COMPOSITIONS FOR TREATING CANCER | |
| EP3708173C0 (en) | PHARMACEUTICAL COMPOSITION CONTAINING MIRNA-3140 FOR THE TREATMENT OF CANCER | |
| EP4096653A4 (en) | COMPOSITIONS FOR TREATING ANGIOLIPOMA | |
| EP3969001A4 (en) | BISFLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS FOR THE TREATMENT OF NOTCH-ACTIVATED BREAST CANCER | |
| EP4422608A4 (en) | Endoxifen for the treatment of cancer | |
| EP4058041C0 (en) | COMPOSITION FOR THE TREATMENT OF EPITHELIAL LESIONS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20231204 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20250314 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07D 243/14 20060101ALI20250310BHEP Ipc: A61K 31/635 20060101ALI20250310BHEP Ipc: A61K 31/5513 20060101ALI20250310BHEP Ipc: A61K 31/44 20060101AFI20250310BHEP |